blood pressure news from FierceBiotech
News
Pharmacopeia cuts 15% of workforce
In an effort to streamline its business and save cash, Pharmacopeia is laying off 15 percent of its workforce and decreasing "other expenses through improved operational efficiencies and increased Read more...
Pharmacopeia shares rise on blood pressure data
Pharmacopeia's shares were up today on trial results for PS433540, a hypertension drug. Data showed 'significant' blood pressure reductions in a Phase IIa study in patients with mild to moderate Read more...
ALSO NOTED: PDL offers bonuses to top execs; Radius earns $28.3M for milestone;Cytokinetics surges on positive data; and much m
> PDL BioPharma says it will pay four top executives nearly $1 million in bonuses through the end of next year to keep them on board as the company undergoes a transformation into an antibody Read more...
Cytos blood pressure jab could grab blockbuster market
Switzerland's Cytos stirred up some excitement with its announcement that new trial data backs up its hopes for a new Read more...
ALSO NOTED: Sirtris, NCI collaborate on cancer models; Kylin expands in Indiana; and much more...
> Sirtris announced a collaboration with the National Cancer Institute to its enzyme activators in cancer models. Read more...
Pfizer snags Encysive in $195M buyout
Pfizer has demonstrated once again just how interested it is in biotech with its $195 Read more...
NicOx pushes new naproxen version for arthritis pain
The Wall Street Journal reports on the progress that NicOx is making advancing a new version of naproxen for relieving arthritis pain. The French biotech is looking for a marketing partner for the Read more...
Cytos vaccine offers radically new approach
Cytos Biotechnology has won a round of kudos for its experimental vaccine to control hypertension. CYT006-AngQb produced positive safety and efficacy data in a small Phase IIa trial of 72 volunteers Read more...
King cuts 20% of workforce
Tennessee-based King Pharmaceuticals said it will cut its workforce by 20 percent due to problems the company is having with its Altace franchise. Last month King Pharmaceuticals lost its fight with Read more...
Wyeth's Pristiq shows benefits in clinical trial
Wyeth says that the nonhormonal desvenlafaxine, or Pristiq, demonstrated significant efficacy against hot flashes and night sweats in a clinical trial--but noted that high blood pressure and other Read more...
Get more blood pressure coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets